The present four-arm, parallel, double-blind randomized controlled trial was designed to evaluate the independent and additive effects of magnesium and melatonin on metabolic profiles and levels of sex hormones in women with PCOS. This evidence concerns the gene PLXNA3 and polycystic ovary syndrome.